NCT03797625

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas of the Prospective, Single Arm Phase II Clinical Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to explore whether endostar combined with IP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens

Detailed description

This study is to explore whether endostar combined with IP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens used as second-line treatment of advanced esophageal squamous cell carcinomas

Conditions

• Esophageal Squamous Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Irinotecan	60mg/m2，D1，8
DRUG	DDP	60mg/m2，D1
DRUG	Endostar	15mg/d，d1-d7 civ

Timeline

• Start date: 2017-05-04
• Primary completion: 2020-12-31
• Completion: 2021-12-31
• First posted: 2019-01-09
• Last updated: 2025-07-23

Locations

1 site across 1 country: China